The Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of Digestive Diseases and Non-digestive System Diseases Associated With Gastrointestinal Symptoms in the Gastrointestinal Tract.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Fecal Microbiota Transplantation
- Sponsor
- Shanghai 10th People's Hospital
- Enrollment
- 10000
- Locations
- 1
- Primary Endpoint
- Comparing the differences in microbiota composition in samples such as feces and small intestinal fluid from patients.
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The exploration of the safety and efficacy of fecal microbiota transplantation in the treatment of non-digestive system diseases associated with gastrointestinal symptoms in the gastrointestinal tract, while also investigating the impact of fecal microbiota transplantation on the intestinal system, and assessing the improvement of symptoms in other systems.Simultaneously optimizing the conditions during the FMT process, identifying the most effective treatment methods to enhance the therapeutic outcomes of FMT.
Investigators
Huanlong Qin
Dean of the hospital
Shanghai 10th People's Hospital
Eligibility Criteria
Inclusion Criteria
- •Being able to tolerate a nasoenteric tube or swallow a capsule.
Exclusion Criteria
- •Intestinal barrier dysfunction. Inability to tolerate enteral nutrition.
Outcomes
Primary Outcomes
Comparing the differences in microbiota composition in samples such as feces and small intestinal fluid from patients.
Time Frame: 0day, 7days, 30days, 3 months, 6months,12 months
Performing 16S rRNA sequencing, metagenomic sequencing, and metabolite analysis on the samples.
Comparing the therapeutic efficacy of patients after FMT.
Time Frame: 0day, 7days, 30days, 3 months, 6months,12 months
Through conducting relevant questionnaire surveys with patients, we can gain insights into the therapeutic efficacy of patients after undergoing FMT.